



3rd February 2025

dorsaVi Announces new deal with prominent US Surgeon focused on lower limb applications for elite athletes

Key Highlights:

- **New commercial research project secured** with prominent US Foot and Ankle Physician and Surgeon, Dr. Chirag Patel who acts as a Resident Injury Expert at ESPN and works with professional athletes from around the world in his medical practice. Recognized as a leading authority in lower extremity sports medicine, he specialises in injury prevention, performance optimization, and athlete longevity. His expertise has earned him numerous awards, global recognition, and prestigious speaking opportunities.
- The project is to be conducted during the first half of 2025 with outputs leading to new insights in the clinical and sporting environments.
- **Why dorsaVi was chosen?** Dr Patel selected dorsaVi sensors over competitors due to dorsaVi's:
 - FDA Cleared status
 - Established expertise in lower limb products within the US sporting and clinical markets
 - Deep AI and algorithmic capabilities within the dorsaVi team.
- The study will rely on dorsaVi's wearable sensor technology and advanced AI and Machine Learning algorithms to drive greater insights into an athletes' movements, aiming to identify the movement traits and patterns that may pre-dispose an athlete to a higher risk of injury.

Melbourne, Australia, 3rd February 2025:

dorsaVi (ASX: DVL), a global leader in FDA cleared wearable sensor technology and human movement analysis, is pleased to announce a new commercial research project with prominent US physician and surgeon, Dr Chirag Patel.

The project will generate \$46,750 USD of revenue for dorsaVi with potential for further work based on the success of this initial project. The project will utilise dorsaVi's wearable sensors, video AI tracking and proprietary Research+ software and firmware applications to optimise the fusion algorithm for high speed, multi-directional sporting and clinical needs.



Figure 1: Dr. Chirag Patel

Dr Chirag Patel is Managing Director of New Horizons Foot and Ankle Associates, as well as New Horizons Concierge Sports Medicine and Peak Performance Laser Institute in the United States. He is also the Founder/CEO of Health AnalySYST and a Resident Injury Expert for ESPN.

New Horizons specialises in non-invasive sports medicine and performance solutions for elite athletes, including clients from the NFL, NBA, MLB, MLS, and USL. Health AnalySYST leverages data-driven metrics to enhance athlete longevity, safety, and performance, providing actionable insights to optimize outcomes and reduce injury risks.

In his role with ESPN, Dr. Chirag Patel, functions as a Resident Injury Expert and is brought into discussions on topics like proper footwear for young athletes to reduce injury risk, current “hot topic” injuries affecting athletes in professional sports, insights on treatments and timelines for return to play, and professional tips for viewers and listeners to optimize health and promote pain-free motion.

dorsaVi and Dr Patel will collaborate on a research project to explore innovative assessment techniques for the foot and ankle during sporting events and training. The study will leverage dorsaVi's cutting-edge wearable sensor technology and advanced AI and Machine Learning algorithms to drive greater insights into an athletes' movements. The goal is to identify movement patterns and traits that may pre-dispose athletes to a higher risk of injury.

The data generated in the project with Dr Patel has the potential to benefit from dorsaVi's planned Blockchain Integration which aims to enhance data security and compliance, reinforcing dorsaVi's leadership in data integrity, privacy, and security. Blockchain technology helps provide a secure, tamper-proof platform for storing and sharing data with stakeholders, reinforcing trust and reliability in the insights generated.

The new contract investigates the capacities of dorsaVi's technology and its' integration into a real-time platform designed to promote professional athlete safety, performance and longevity during training and game time.

This release has been authorised for lodgement by the Company's Board of Directors.

- ENDS -

For further information about dorsaVi, please contact:

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
Email: ar@dorsaVi.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsaVi.com